药品
医学
熊去氧胆酸
肝损伤
药物开发
重症监护医学
消胆胺
内科学
药理学
胆固醇
作者
Meng Li,Qiong Luo,Yanyan Tao,Xin Sun,Chenghai Liu
标识
DOI:10.3389/fphar.2021.806249
摘要
Drug-induced liver injury (DILI) has become a serious public health problem. For the management of DILI, discontinuation of suspicious drug or medicine is the first step, but the treatments including drugs and supporting approaches are needed. Reference to clinical patterns and disease severity grades of DILI, the treatment drugs were considered to summarize into hepatoprotective drugs (N-acetylcysteine and Glutathione, Glycyrrhizin acid preparation, Polyene phosphatidylcholine, Bicyclol, Silymarin), anticholestatic drug (Ursodeoxycholic acid, S-adenosylmethionine, Cholestyramine), immunosuppressants (Glucocorticoids) and specific treatment agents (L-carnitine, Anticoagulants). The current article reviewed the accumulated literature with evidence-based medicine researches for DILI in clinical practice. Also the drawbacks of the clinical studies involved in the article, unmet needs and prospective development for DILI therapy were discussed.
科研通智能强力驱动
Strongly Powered by AbleSci AI